0.55Open0.60Pre Close21 Volume3.69K Open Interest5.00Strike Price1.43KTurnover111.73%IV-0.53%PremiumJan 17, 2025Expiry Date0.68Intrinsic Value100Multiplier11DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.7733Delta0.2678Gamma6.68Leverage Ratio-0.0154Theta0.0011Rho5.17Eff Leverage0.0030Vega
Torrid Stock Discussion
Dow Jones· 3 mins ago
Torrid Reports Third Quarter Fiscal 2024 Results
5 minutes ago, 1:05 PM PST
Via BusinessWire
• Delivered Net Sales of $263.8 million
• Generated gross margin expansion of 285 basis points to 36.1%
• Net Loss of $1.2 million compared to Net Loss of $2.7 million last year
• Updated 2024 Net Sales and Adjusted EBITDA(1) Outlook
📊⚡️📊
$Yield10 Bioscience (YTEN.US)$ $Lytus Technologies Holdings (LYT.US)$ $Avalo Therapeutics (AVTX.US)$ $Gamida Cell (GMDA.US)$ $Torrid (CURV.US)$ $Qilian International (QLI.US)$
📊⚡️📊
📊⚡️📊
CURV soared 26% to trade at $6.15 shortly before 4:45 p.m. ET after the company reported a $0.04 loss per share – narrower than the $0.07 analysts had reportedly expected.
The company also recorded $293.5 million of quarterly revenues vs. the $276....
No comment yet